Over the past few decades, miR-106a has been reported to be involved in promoting the proliferation of endometrial cancer RL95-2 cells and inhibiting cell apoptosis 43, in attenuating hyperglycemia induced vascular endothelial cell dysfunction through targeting HMGB1 44, in modulation of tumor cell growth 45. The gene discussed is HMGB1; the disease is neoplasm.